Drug Trial Radar · NCT06397313
RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
36
Actual
Start
Sep 19, 2024
Primary completion
Jun 30, 2026
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- Ryvu Therapeutics SAIndustry
- Sponsor type
- Industry
- First posted
- May 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this clinical trial is to evaluate the efficacy (how well the drug works), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the study drug, RVU120, in treating adult patients with intermediate or high-risk, primary or secondary myelofibrosis. RVU120 will be given as a single agent or in combination with ruxolitinib.
Conditions
- Myelofibrosis
Interventions
RVU120Drug
RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
RuxolitinibDrug
Ruxolitinib is a kinase inhibitor which inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the number of participants with a response (anti-cancer activity) to RVU120 when administered as a single agent or in combination with ruxolitinibTime frame: 12 months
Locations
18 sites in 2 countries. Site status is shown where the registry gives one.
Policlinico Sant'Orsola-Malpighi
Bologna, Italy
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Brescia, Italy
Azienda Ospedaliero Universitaria Policlinico "G. Rodolico - San Marco"
Catania, Italy
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l.
Meldola, Italy
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
Milan, Italy
Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej
Biała Podlaska, Poland
Szpital Uniwersytecki nr 2 im. dr Jana Biziela
Bydgoszcz, Poland
M2M Med. Sp. z o.o. Sp. j.
Chorzów, Poland
Centrum Wsparcia Badań Klinicznych UCK Ośrodek Badań Klinicznych Wczesnych Faz
Gdansk, Poland
Pratia Hematologia Sp. z o.o.
Katowice, Poland
Świętokrzyskie Centrum Onkologii Samodzielny Publiczny Zakład Opieki Zdrowotnej
Kielce, Poland
Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie
Krakow, Poland
Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie
Lublin, Poland
Wojewódzki Szpital Zespolony im. L. Rydygiera w Toruniu
Torun, Poland
Lux Med Onkologia Sp. z o.o.
Warsaw, Poland
Wojskowy Instytut Medyczny Państwowy Instytut Badawczy
Warsaw, Poland
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu
Wroclaw, Poland
Szpital Uniwersytecki Imienia Karola Marcinkowskiego w Zielonej Gorze Sp. z o. o.
Zielona Góra, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.